A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
NCT03821610
Active Not Recruiting
The current national acute lymphoblastic leukaemia (ALL) trial in adults investigated whether a low (reduced) intensity chemotherapy regimen prior to transplant could improve the outcome of patients with ALL who are over 40 years of age. The results (60% 2 year survival) are very encouraging but patients who come to transplant with small amounts of 'residual' disease had less good outcomes. The goal of this trial is to see if a slightly stronger chemotherapy regimen (involving total body irradia... Read More
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
05/14/2024
Locations: Heart of England Nhs Foundation Trust, Birmingham, Not set +21 locations
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
NCT02308527
Active Not Recruiting
The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or Topotecan-Temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma. Also, to investigate whether the addition of Irinotecan or Topotecan to Temozolomide increases the activity of chemotherapy.The primary objective of the study is the best response (Complete Response or Partial Respons... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
05/13/2024
Locations: St Anna Children's Hospital and CCRI/Studies and Statistics, Vienna, Not set +9 locations
Conditions: Neuroblastoma
Register for Updates
MUK Nine b: OPTIMUM Treatment Protocol
NCT03188172
Active Not Recruiting
To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab (Darzalex) \& dexamethasone in combination with low-dose cyclophosphamide is sufficiently active in a high risk population of myeloma patients, to take forward into a phase III trial compared to standard treatment.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/10/2024
Locations: Queen Elizabeth Hospital, Birmingham, Not set +20 locations
Conditions: Multiple Myeloma
Register for Updates
Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
NCT04061512
Recruiting
Waldenström's macroglobulinaemia (WM) is a rare type of slow growing lymphoma. It develops when white blood cells grow abnormally. Typically a disease of the elderly, the median age of presentation is \>70 years and the current treatment for WM is unsatisfactory, with incomplete responses and inevitable recurrence. Therefore there is a need to find alternative treatments that are more effective, leading to lasting responses and improved quality of life. The RAINBOW study is a phase 2-3 trial a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Royal United Hospital, Bath, Bath, Not set +24 locations
Conditions: Waldenstrom Macroglobulinemia
Register for Updates
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
NCT00678327
Completed
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 (FDG)-PET/CT scan, done before, during, and after chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment. It is not yet known whether FDG-PET/CT imaging is effective in assessing response to chemotherapy in patients with newly diagnosed Hodgkin lymphoma. PURPOSE: This randomized phase III trial is studying FDG-PET/CT imaging to see how well it works in assessing response to chemotherapy... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/07/2024
Locations: Southampton General Hospital, Southampton, England
Conditions: Lymphoma
Register for Updates
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06399393
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +117 locations
Conditions: Multiple Myeloma
Register for Updates
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
NCT02265770
Recruiting
The overall aim of this project is to improve the outcome of patients diagnosed with ependymoma by improving and harmonising the staging and the standard of care of this patient population and to improve the investigators understanding of the underlying biology thereby informing future treatment. The program will evaluate new strategies for diagnosis (centralized reviews of pathology and imaging) and new therapeutic strategies in order to develop treatment recommendations. Patients will be str... Read More
Gender:
ALL
Ages:
22 years and below
Trial Updated:
04/25/2024
Locations: Medical University of Graz-Department of Pediatrics and Adolescent Medicine, Graz, Not set +39 locations
Conditions: Childhood Ependymoma
Register for Updates
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
NCT01659658
Terminated
The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB improves hematologic response, 2-year vital organ (that is, heart or kidney) deterioration and mortality rate versus a physician's choice of a chemotherapy regimen in participants diagnosed with relapsed or refractory systemic light chain (AL) amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California +65 locations
Conditions: Relapsed or Refractory Systemic Light Chain Amyloidosis
Register for Updates
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
NCT06205290
Withdrawn
The purpose of this study is to compare the efficacy and safety of liso-cel vs Investigator's Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult participants with R/R CLL or SLL, whose disease has failed treatment with both BTKi and BCL2i targeted therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +47 locations
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Register for Updates
An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
NCT03817853
Completed
This open-label, single arm study will evaluate the safety of obinutuzumab administered as a short duration infusion (SDI; target 90-minute infusion) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in participants with previously untreated advanced follicular lymphoma (FL). The study has two phases: in the first phase, participants will receive the first cycle of obinutuzumab-based chemotherapy (G-chemo) induction therapy as usual with the first three infusions of obinut... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Rocky Mountain Cancer Center; Medical Oncology, Boulder, Colorado +32 locations
Conditions: Advanced Follicular Lymphoma
Register for Updates
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
NCT00036868
Completed
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, methotrexate, and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with trastuzumab may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining combination chemotherapy with... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
03/07/2024
Locations: Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Not set +12 locations
Conditions: Breast Cancer
Register for Updates
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
NCT02684708
Active Not Recruiting
The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy intensification randomisation in intermediate and advanced classical Hodgkin lymphoma to compensate for reduction in radiotherapy.
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/27/2024
Locations: Royal Children's Hospital and Monash Medical Centre Royal Children's Hospital, Victoria Park, Not set +18 locations
Conditions: Classical Hodgkin Lymphoma
Register for Updates